Unlock instant, AI-driven research and patent intelligence for your innovation.

Adjuvant and vaccine composition comprising sting agonist

A technology of vaccine composition and immune adjuvant, applied in the field of immune adjuvant composition, can solve the problems of increasing the incidence of mutation, problems, safety of occasional self-replication, etc., and achieve the effect of reducing infection

Pending Publication Date: 2021-05-07
QURATIS INC
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although vaccines made from live or attenuated bacteria are very effective, safety issues often arise due to the potential for failure, occasional self-replication, etc.
When using a vaccine prepared from dead bacteria, although it is effective for treatment, there is a problem that toxic substances such as LPS are contained therein or live bacteria are present (Ryan EJ et al., 2001), and, in order to overcome the above limitations, The developed DNA vaccine also has the possibility of increasing the incidence of mutation (mutagenic) or becoming an oncogenic gene (oncogenic) even if it enters the host's genome (genome)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adjuvant and vaccine composition comprising sting agonist
  • Adjuvant and vaccine composition comprising sting agonist
  • Adjuvant and vaccine composition comprising sting agonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0042] Hereinafter, the present invention will be further described in detail through examples. These embodiments are only used to further describe the present invention in detail, and it is obvious to those skilled in the art that, according to the gist of the present invention, the scope of the present invention is not limited by these embodiments.

Embodiment 1

[0044] Example 1: Confirmation of the role of interferon gene-stimulating protein agonists as immune adjuvants

[0045] The following experiment was performed to confirm whether Stimulator of interferon genes (STING) can be used as an immune adjuvant for Mycobacterium tuberculosis.

[0046] 1.1. Experimental animals

[0047] Experiments were performed using 6-week-old postnatal female C57BL / 6 mice (Japan SLC, Inc. Shijuoka, Japan) free of specific pathogens in the confined space of the ABSL-3 Biohazard Animal Laboratory within the Clinical Medical Research Center of Yonsei University, Korea In , mice were maintained by providing sterile commercial feed and water.

[0048] 1.2. Experimental design

[0049] In order to confirm whether c-di-GMP (invivogen), a stimulator of interferon genes (STING, Stimulator of interferon genes), can be used alone as an immune adjuvant (adjuvant), animal experiments were carried out. The specific experimental method is shown in figure 1 In ...

Embodiment 2

[0072] Example 2: Confirmation of synergistic effect of interferon gene-stimulating protein agonist and immune adjuvant

[0073] The following experiment was carried out to confirm the synergistic effect of simultaneous use of Stimulator of interferongenes (STING) agonist and monophosphoryl lipid A (MPL), which is a known immune adjuvant (adjuvant) .

[0074] 2.1. Experimental animals

[0075] Experiments were performed using 6-week-old postnatal female C57BL / 6 mice (Japan SLC, Inc. Shijuoka, Japan) free of specific pathogens in the confined space of the ABSL-3 Biohazard Animal Laboratory within the Clinical Medical Research Center of Yonsei University, Korea In , mice were maintained by providing sterile commercial feed and water.

[0076] 2.2. Experimental design

[0077] Animal experiments were carried out to confirm whether a synergistic effect occurs when c-di-GMP (invivogen) and a known immune adjuvant are used simultaneously. The specific experimental method is sh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an adjuvant composition and a vaccine composition, each comprising a STING agonist. The adjuvant composition and the vaccine composition according to the present invention, which each comprise a STING agonist, are identified not only to have the ability to effectively activate various immune responses within the body, but also to exhibit the effect of significantly reducing the infection caused by causative agents of tuberculosis. Thus, when used in combination of vaccines against other pathogens, the compositions are expected to effectively reduce infection caused by various pathogens as well as causative agents of tuberculosis by remarkably augmenting effects of the conventional vaccines for preventing infection.

Description

technical field [0001] The present invention relates to an immune adjuvant composition comprising an interferon gene-stimulating protein agonist, a vaccine composition, and a method for preventing infectious diseases using the same. [0002] Furthermore, the present invention relates to a vaccine composition comprising an interferon gene-stimulating protein agonist and an immune adjuvant, and a method for preventing infectious diseases using the same. Background technique [0003] Various strategies will be used in the development of a vaccine. Although vaccines prepared from live or attenuated bacteria are very effective, safety concerns often arise due to the potential for failure and occasional self-replication. When a vaccine prepared from dead bacteria is used, although it is effective for treatment, there are problems that toxic substances such as LPS are contained therein or live bacteria are present (Ryan EJ et al., 2001), and in order to overcome the above limitati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/04A61P31/06A61K39/00
CPCA61K39/04A61P31/06A61K2039/55561A61K2039/55566A61K2039/555A61K2039/57A61K39/39A61K2039/55511
Inventor 慎城宰吴明烈
Owner QURATIS INC